Details

Autor(en) / Beteiligte

• Smeaton, Laura M
• Kileel, Emma M
• Grinsztejn, Beatriz
• Gardner, Edward M
• Starr, Kate
• Murry, Melissa L
• Desvigne-Nickens, Patrice
• Alston-Smith, Beverly
• Waclawiw, Myron A
• Cooper-Arnold, Katharine
• Madruga, José V
• Sangle, Shashi
• Fitch, Kathleen V
• Zanni, Markella V
• Douglas, Pamela S
• Ribaudo, Heather J
• Grinspoon, Steven K
• Klingman, Karin L

Titel

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

Ist Teil von

• The Journal of infectious diseases, 2020-07, Vol.222 (Supplement_1), p.S31-S40

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2020

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.